Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Reviews in Clinical and Experimental Pharmacology
  4. Fast Track Articles
  5. Fast Track Article
image of Bleeding vs Thrombosis: Treatment Strategy for Women Having Large Uterine Fibroids and DVT

Abstract

Large uterine fibroids (UFs) are clonal neoplasms of the uterus that form during the mid and late-aged women. Such women generally consume oral contraceptive pills, tranexamic acid, or NSAIDS to manage heavy menstrual bleeding (HMB) and associated complications while waiting for a conclusive procedure or avoiding hysterectomy. The procoagulant effect of these medicinal agents can result in venous stasis of the lower limbs, leading to deep vein thrombosis (DVT), a challenging complication with HMB. We examine the complicated state of heavy bleeding with thrombosis and explore better management options. It has been seen that women with hypothyroidism have an increased risk of getting DVT due to an alteration in the coagulation system. These incidences are mostly associated with higher uterine weight, which is related to the extrinsic compression of the inferior vena cava. In such cases, the occurrence of postoperative thrombosis is riskier if hysterectomy/myomectomy is the only option. Utilization of appropriate anticoagulants with modification of the steroid-hormone system using hormone agonists or antagonists (., levonorgestrel intrauterine system, high-dose progestin-only therapy, danazol, aromatase inhibitors, Vitamin-D supplements or selective estrogen receptor modulators) could be an effective technique, but adverse consequences of continued use should be monitored. More research is needed into the basic biology associated with the role of growth factors and genetic alterations in these malignancies. The development of new leiomyomas following conservative therapy is also a significant issue.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crcep/10.2174/0127724328317631240925051326
2024-10-09
2025-04-02

  • From This Site

    /content/journals/crcep/10.2174/0127724328317631240925051326
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Orlando M.S. Sinha A. Yao M. Shippey E. Kho R.M. Perioperative venous thromboembolism in patients undergoing hysterectomy for fibroids: A nationwide sample. J. Minim. Invasive Gynecol. 2022 29 11 S2 S3 10.1016/j.jmig.2022.09.020
    [Google Scholar]
  2. Shaffer R.K. Fast A.M. Vu K.N. Dobberfuhl A.D. Ghanouni P. Chen B. Association between uterine fibroid findings on pelvic MRI, bleeding symptoms, and quality of life [19Q]. Obstet. Gynecol. 2018 131 1 189S 10.1097/01.AOG.0000533231.44638.dd
    [Google Scholar]
  3. Kyrle P.A. Eichinger S. Deep vein thrombosis. Lancet 2005 365 9465 1163 1174 10.1016/S0140‑6736(05)71880‑8 15794972
    [Google Scholar]
  4. Heit J.A. O’Fallon W.M. Petterson T.M. Lohse C.M. Silverstein M.D. Mohr D.N. Melton L.J. III Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch. Intern. Med. 2002 162 11 1245 1248 10.1001/archinte.162.11.1245 12038942
    [Google Scholar]
  5. Anton A. Campreciós G. Pérez-Campuzano V. Orts L. García-Pagán J.C. Hernández-Gea V. The pathophysiology of portal vein thrombosis in cirrhosis: Getting deeper into Virchow’s Triad. J. Clin. Med. 2022 11 3 800 10.3390/jcm11030800 35160251
    [Google Scholar]
  6. Latif H. Baez Sosa V. Farid S. Fernandez S. Hazen N. Morozov V. Fitzpatrick K.W. Venous Thromboembolism in Women with Uterine Fibroids. Blood 2020 136 Suppl. 1 28 29 10.1182/blood‑2020‑136678
    [Google Scholar]
  7. Tinawi M. Massive uterine fibroid resulting in extensive deep venous thrombosis, compartment syndrome and rhabdomyolysis. Arch. Intern. Med. Res. 2020 3 1 69 73 10.26502/aimr.0024
    [Google Scholar]
  8. Anagani M. Agrawal P. Agrawal R. Acute right lower limb deep venous thrombosis due to pressure from large adenomyotic uterus-laparoscopic management. Int. J. Reprod. Contracept. Obstet. Gynecol. 2020 9 11 4749 4753 10.18203/2320‑1770.ijrcog20204850
    [Google Scholar]
  9. Ciebiera M. Ali M. Zgliczyńska M. Skrzypczak M. Al-Hendy A. Vitamins and uterine fibroids: Current data on pathophysiology and possible clinical relevance. Int. J. Mol. Sci. 2020 21 15 5528 10.3390/ijms21155528 32752274
    [Google Scholar]
  10. Ciebiera M. Włodarczyk M. Zgliczyński S. Łoziński T. Walczak K. Czekierdowski A. The role of miRNA and related pathways in pathophysiology of uterine fibroids—from bench to bedside. Int. J. Mol. Sci. 2020 21 8 3016 10.3390/ijms21083016 32344726
    [Google Scholar]
  11. Okonofua F. Uterine Fibroid and Hysterectomy. Contemporary Obstetrics and Gynecology for Developing Countries Cham Springer 2021 451 460
    [Google Scholar]
  12. Fang C. Yang J. Ding W. Li K. Weng D. Wu P. Chen G. Ma D. Wei J. Incidence of symptomatic deep vein thrombosis after gynecological surgery: A retrospective study in Chinese population. Eur. J. Gynaecol. Oncol. 2019 40 6 939 942 10.12892/ejgo4675.2019
    [Google Scholar]
  13. Levin V Booth R Minassian S. Bleeding Disorders and ART. Textbook of Assisted Reproduction Berlin, Heidelberg Springer Link 2020 10.1007/978‑981‑15‑2377‑9_35
    [Google Scholar]
  14. Yu PT Chen CY Lin CY Uterine Myoma─ Induced Venal Thrombosis and Acute Pulmonary Thromboembolism: 2 Case Reports. Airiti Lib. 2019 34 3 133 138
    [Google Scholar]
  15. Finianos E.S. Yacoub S.F. Chammas M.F. Ovarian vein thrombosis complicated by pulmonary embolism after cesarean delivery in the presence of a large fibroid: Case report and literature review of contributing factors. Case Rep. Obstet. Gynecol. 2021 2021 1 7 10.1155/2021/6389713 34540300
    [Google Scholar]
  16. Ramzi D.W. Leeper K.V. DVT and pulmonary embolism: Part I. Diagnosis. Am. Fam. Physician 2004 69 12 2829 2836 15222648
    [Google Scholar]
  17. Tinelli A. Vinciguerra M. Malvasi A. Andjić M. Babović I. Sparić R. Uterine fibroids and diet. Int. J. Environ. Res. Public Health 2021 18 3 1066 10.3390/ijerph18031066 33504114
    [Google Scholar]
  18. Donnez J. Carmona F. Maitrot-Mantelet L. Dolmans M.M. Chapron C. Uterine disorders and iron deficiency anemia. Fertil. Steril. 2022 118 4 615 624 10.1016/j.fertnstert.2022.08.011 36182260
    [Google Scholar]
  19. Kirschen G.W. AlAshqar A. Miyashita-Ishiwata M. Reschke L. El Sabeh M. Borahay M.A. Vascular biology of uterine fibroids: Connecting fibroids and vascular disorders. Reproduction 2021 162 2 R1 R18 10.1530/REP‑21‑0087 34034234
    [Google Scholar]
  20. Donnez J. Uterine fibroids and progestogen treatment: Lack of evidence of its efficacy: A review. J. Clin. Med. 2020 9 12 3948 10.3390/jcm9123948 33291422
    [Google Scholar]
  21. Abo S. Smith D. Stadt M. Layton A. Modelling female physiology from head to Toe: Impact of sex hormones, menstrual cycle, and pregnancy. J. Theor. Biol. 2022 540 111074 10.1016/j.jtbi.2022.111074 35227731
    [Google Scholar]
  22. Yin H. Lo J.H. Kim J.Y. Marsh E.E. Kim J.J. Ghosh A.K. Bulun S. Chakravarti D. Expression profiling of nuclear receptors identifies key roles of NR4A subfamily in uterine fibroids. Mol. Endocrinol. 2013 27 5 726 740 10.1210/me.2012‑1305 23550059
    [Google Scholar]
  23. Ranhotra H.S. The NR4A orphan nuclear receptors: Mediators in metabolism and diseases. J. Recept. Signal Transduct. Res. 2015 35 2 184 188 10.3109/10799893.2014.948555 25089663
    [Google Scholar]
  24. Stewart E.A. Laughlin-Tommaso S.K. Catherino W.H. Lalitkumar S. Gupta D. Vollenhoven B. Uterine fibroids. Nat. Rev. Dis. Primers 2016 2 1 16043 10.1038/nrdp.2016.43
    [Google Scholar]
  25. Zannotti A. Greco S. Pellegrino P. Giantomassi F. Delli Carpini G. Goteri G. Ciavattini A. Ciarmela P. Macrophages and immune responses in uterine fibroids. Cells 2021 10 5 982 10.3390/cells10050982 33922329
    [Google Scholar]
  26. Gao L. Ge L. Zhu M. Yao X. Association between tumor necrosis factor α and uterine fibroids. Medicine (Baltimore) 2020 99 33 e21667 10.1097/MD.0000000000021667 32872031
    [Google Scholar]
  27. Hamzaq F.M. Al-Hilli N.M. Correlation between Serum Interleukin-33 Level and Uterine Fibroids. Prof.(Dr). RK Sharma. 2020 20 4 4722
    [Google Scholar]
  28. Narzullayeva N.S. Innovative methods of diagnosis and treatment in women with infertility associated with uterine fibroids. J. Pharm. Negat. Results 2022 4 3313 3321 10.47750/pnr.2022.13.S08.407
    [Google Scholar]
  29. Hou A. Yan Z. Zhang Y. Hou J. Oral administration of mifepristone combined with ultrasound-guided radiofrequency ablation in treating patients with uterine fibroids: Efficacy, safety, and alternations of inflammatory cytokines, adhesion molecules, and growth factors. J. Nanomater. 2021 2021 1 7 10.1155/2021/9946224
    [Google Scholar]
  30. Baranov V.S. Osinovskaya N.S. Yarmolinskaya M.I. Pathogenomics of uterine fibroids development. Int. J. Mol. Sci. 2019 20 24 6151 10.3390/ijms20246151 31817606
    [Google Scholar]
  31. De Gregorio A Bekes I De-Gregorio N Andres S Hoffmeister D Swerev T Friedl TW Janni W Ebner F Comparison of preoperative serum VEGF in leiomyosarcoma and uterus myomatosus patients: A proof of concept study. J. Clin. Oncol. 2019 37 15 e17117 10.1200/JCO.2019.37.15_suppl.e17117
    [Google Scholar]
  32. Yang M.J. Yu R.Q. Chen W. Chen J.Y. Wang Z.B. A prediction of NPVR≥ 80% of ultrasound-guided high-intensity focused ultrasound ablation for uterine fibroids. Front. Surg. 2021 8 663128 10.3389/fsurg.2021.663128 34150838
    [Google Scholar]
  33. Zeng L. Yang K. Liu H. Zhang G. A network pharmacology approach to investigate the pharmacological effects of Guizhi Fuling Wan on uterine fibroids. Exp. Ther. Med. 2017 14 5 4697 4710 10.3892/etm.2017.5170 29201170
    [Google Scholar]
  34. Yang Q. Al-Hendy A. Update on the Role and Regulatory Mechanism of Extracellular Matrix in the Pathogenesis of Uterine Fibroids. Int. J. Mol. Sci. 2023 24 6 5778 10.3390/ijms24065778 36982852
    [Google Scholar]
  35. Ali M. Esfandyari S. Al-Hendy A. Evolving role of microRNAs in uterine fibroid pathogenesis: Filling the gap! Fertil. Steril. 2020 113 6 1167 1168 10.1016/j.fertnstert.2020.04.011 32482253
    [Google Scholar]
  36. Chuang T.D. Quintanilla D. Boos D. Khorram O. Long noncoding RNA MIAT modulates the extracellular matrix deposition in leiomyomas by sponging MiR-29 family. Endocrinology 2021 162 11 bqab186 10.1210/endocr/bqab186 34491311
    [Google Scholar]
  37. Chuang T.D. Rehan A. Khorram O. Tranilast induces MiR-200c expression through blockade of RelA/p65 activity in leiomyoma smooth muscle cells. Fertil. Steril. 2020 113 6 1308 1318 10.1016/j.fertnstert.2019.12.002 32199621
    [Google Scholar]
  38. Bernstein D.L. Jiang X. Rom S. let-7 microRNAs: Their role in cerebral and cardiovascular diseases, inflammation, cancer, and their regulation. Biomedicines 2021 9 6 606 10.3390/biomedicines9060606 34073513
    [Google Scholar]
  39. Leppert P.C. Jayes F.L. Segars J.H. The extracellular matrix contributes to mechanotransduction in uterine fibroids. Obstet. Gynecol. Int. 2014 2014 1 12 10.1155/2014/783289 25110476
    [Google Scholar]
  40. Moro E. Degli Esposti E. Borghese G. Manzara F. Zanello M. Raimondo D. Gava G. Arena A. Casadio P. Meriggiola M.C. Seracchioli R. The impact of hormonal replacement treatment in postmenopausal women with uterine fibroids: A state-of-the-art review of the literature. Medicina (Kaunas) 2019 55 9 549 10.3390/medicina55090549 31480288
    [Google Scholar]
  41. Mlodawska O.W. Saini P. Parker J.B. Wei J.J. Bulun S.E. Simon M.A. Chakravarti D. Epigenomic and enhancer dysregulation in uterine leiomyomas. Hum. Reprod. Update 2022 28 4 518 547 10.1093/humupd/dmac008 35199155
    [Google Scholar]
  42. El Andaloussi A. Al-Hendy A. Ismail N. Boyer T.G. Halder S.K. Introduction of somatic mutation in MED12 induces Wnt4/β-catenin and disrupts autophagy in human uterine myometrial cell. Reprod. Sci. 2020 27 3 823 832 10.1007/s43032‑019‑00084‑7 32046450
    [Google Scholar]
  43. Koltsova A. Efimova O. Pendina A. A view on uterine leiomyoma genesis through the prism of genetic, epigenetic and cellular heterogeneity. Int. J. Mol. Sci. 2023 24 6 5752 10.3390/ijms24065752 36982825
    [Google Scholar]
  44. Das D. Banerjee A. Jena A.B. Duttaroy A.K. Pathak S. Essentiality, relevance, and efficacy of adjuvant/combinational therapy in the management of thyroid dysfunctions. Biomed. Pharmacother. 2022 146 112613 10.1016/j.biopha.2022.112613 35062076
    [Google Scholar]
  45. Wei W.T. Liu P.P.S. Lin S.M. Peng C.C.H. Wang J.H. Huang H.K. Loh C.H. Hypothyroidism and the risk of venous thromboembolism: A nationwide cohort study. Thromb. Haemost. 2020 120 3 505 514 10.1055/s‑0039‑3402761 32028535
    [Google Scholar]
  46. Garg D.S.S. Ramalakshmi D.S. Menstrual disorders in chronic kidney disease: Causes and management. Int. J. Clin. Obstetrics Gynaecol. 2020 4 2 353 358 10.33545/gynae.2020.v4.i2f.549
    [Google Scholar]
  47. Li S. Li W. Sheng B. Zhu X. Relationship between thyroid disorders and uterine fibroids among reproductive-age women. Endocr. J. 2021 68 2 211 219 10.1507/endocrj.EJ20‑0340 33028746
    [Google Scholar]
  48. Yuk J.S. Kim J.M. Uterine fibroids increase the risk of thyroid goiter and thyroid nodules. Sci. Rep. 2022 12 1 6620 10.1038/s41598‑022‑10625‑x 35459918
    [Google Scholar]
  49. Dolmans M.M. Cacciottola L. Donnez J. Conservative management of uterine fibroid-related heavy menstrual bleeding and infertility: Time for a deeper mechanistic understanding and an individualized approach. J. Clin. Med. 2021 10 19 4389 10.3390/jcm10194389 34640407
    [Google Scholar]
  50. Cayton Vaught K.C. Facadio Antero M. Maher J.Y. Cross C.I. Fibroids and endometrial receptivity/embryo implantation. Fibroids Reprod. 2020 34 23 32 10.1201/9780203728987‑3
    [Google Scholar]
  51. Levai A.M. Rotar I.C. Muresan D. Torsion of a uterine leiomyoma – a rare cause of hemoperitoneum; a case report and review of the literature. Med. Ultrason. 2019 21 1 77 82 10.11152/mu‑1784 30779835
    [Google Scholar]
  52. Brewster L.M. Perrotta I.D. Jagernath Z. Taherzadeh Z. van Montfrans G.A. Ultrastructural changes in resistance arterioles of normotensive and hypertensive premenopausal women with uterine fibroids. Ultrastruct. Pathol. 2023 47 2 104 115 10.1080/01913123.2023.2171168 36780499
    [Google Scholar]
  53. Shiota M. Kotani Y. Umemoto M. Tobiume T. Tsuritani M. Shimaoka M. Hoshiai H. Deep-vein thrombosis is associated with large uterine fibroids. Tohoku J. Exp. Med. 2011 224 2 87 89 10.1620/tjem.224.87 21576892
    [Google Scholar]
  54. Raguramana S. Vathanan V. Lower extremity deep venous thrombosis and pulmonary embolism associated with an uterine leiomyoma. Sri Lanka J. Obstetrics Gynaecol. 2020 42 1 32 10.4038/sljog.v42i1.7931
    [Google Scholar]
  55. Kościelna-Buczek K. Mędoń E. Widuch M. Kończyk B. Kuczmik W. Urbanek T. Lumbar overlordosis—towards the better understanding of the May-Thurner syndrome pathogenesis. Chirurgia Polska. 2021 23 2 1 10
    [Google Scholar]
  56. Khaund A. Lumsden M.A. Impact of fibroids on reproductive function. Best Pract. Res. Clin. Obstet. Gynaecol. 2008 22 4 749 760 10.1016/j.bpobgyn.2008.01.009 18547868
    [Google Scholar]
  57. Pandurevic S. Macut D. Fanelli F. Pagotto U. Gambineri A. Biomediators in polycystic ovary syndrome and cardiovascular risk. Biomolecules 2021 11 9 1350 10.3390/biom11091350 34572562
    [Google Scholar]
  58. Navarro A. Bariani M.V. Yang Q. Al-Hendy A. Understanding the impact of uterine fibroids on human endometrium function. Front. Cell Dev. Biol. 2021 9 633180 10.3389/fcell.2021.633180 34113609
    [Google Scholar]
  59. Ali M. Chaudhry Z.T. Al-Hendy A. Successes and failures of uterine leiomyoma drug discovery. Expert Opin. Drug Discov. 2018 13 2 169 177 10.1080/17460441.2018.1417381 29254389
    [Google Scholar]
  60. Moulder J.K. Siedhoff M.T. Till S.R. Moll S. Management considerations for patients with uterine fibroids and concurrent venous thromboembolism. Curr. Opin. Obstet. Gynecol. 2016 28 4 329 335 10.1097/GCO.0000000000000286 27253238
    [Google Scholar]
  61. Serfaty D. Update on the contraceptive contraindications. J. Gynecol. Obstet. Hum. Reprod. 2019 48 5 297 307 10.1016/j.jogoh.2019.02.006 30796985
    [Google Scholar]
  62. James PD Women and bleeding disorders: Diagnostic challenges. Hematology Am. Soc. Hematol. Educ. Program. 2020 2020 1 547 552 10.1182/hematology.2020000140
    [Google Scholar]
  63. Parazzini F. Chiaffarino F. Polverino G. Chiantera V. Surace M. La Vecchia C. Uterine fibroids risk and history of selected medical conditions linked with female hormones. Eur. J. Epidemiol. 2003 19 3 249 253 10.1023/B:EJEP.0000020448.43323.2a 15117118
    [Google Scholar]
  64. Keenan L. Kerr T. Duane M. Van Gundy K. Systematic review of hormonal contraception and risk of venous thrombosis. Linacre Q. 2018 85 4 470 477 10.1177/0024363918816683 32431379
    [Google Scholar]
  65. Goldhaber S.Z. Risk factors for venous thromboembolism. J. Am. Coll. Cardiol. 2010 56 1 1 7 10.1016/j.jacc.2010.01.057 20620709
    [Google Scholar]
  66. Pickar J.H. MacNeil T. Ohleth K. SERMs: Progress and future perspectives. Maturitas 2010 67 2 129 138 10.1016/j.maturitas.2010.05.009 20580502
    [Google Scholar]
  67. Pillai L.S. Regidi S. Varghese S.D. Ravindran S. Maya V. Varghese J. Gopi M. Nonhormonal selective estrogen receptor modulator 1‐(2‐(4‐{(3R, 4S)‐7‐Methoxy‐2, 2‐dimethyl‐3‐phenyl‐chroman‐4yl} phenoxy) ethyl) pyrrolidine hydrochloride (ormeloxifene hydrochloride) for the treatment of breast cancer. Drug Dev. Res. 2018 79 6 275 286 10.1002/ddr.21440 30284735
    [Google Scholar]
  68. McCormack P.L. Tranexamic Acid. Drugs 2012 72 5 585 617 10.2165/11209070‑000000000‑00000 22397329
    [Google Scholar]
  69. Berntorp E. Follrud C. Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb. Haemost. 2001 86 2 714 715 11522029
    [Google Scholar]
  70. Bofill Rodriguez M. Lethaby A. Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Libr. 2019 2019 9 CD000400 10.1002/14651858.CD000400.pub4 31535715
    [Google Scholar]
  71. Balkansky S. Peikova L. Grigorov E. Getov I. A review of the use of low-dose acetylsalicylic acid for antithrombotic therapy. S’rdechno-s’ dovi Zabolyavaniya/Medical Review-. Cardiovasc. Dis. 2014 45 3 3 9
    [Google Scholar]
  72. Evans J. Salamonsen L.A. Inflammation, leukocytes and menstruation. Rev. Endocr. Metab. Disord. 2012 13 4 277 288 10.1007/s11154‑012‑9223‑7 22865231
    [Google Scholar]
  73. Maybin J.A. Critchley H.O.D. Medical management of heavy menstrual bleeding. Womens Health (Lond. Engl.) 2016 12 1 27 34 10.2217/whe.15.100 26695687
    [Google Scholar]
  74. De La Cruz M.S.D. Buchanan E.M. Uterine fibroids: Diagnosis and treatment. Am. Fam. Physician 2017 95 2 100 107 28084714
    [Google Scholar]
  75. DiVasta A.D. Laufer M.R. Gordon C.M. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis. J. Pediatr. Adolesc. Gynecol. 2007 20 5 293 297 10.1016/j.jpag.2007.04.008 17868896
    [Google Scholar]
  76. Kavoussi S.K. Esqueda A.S. Jukes L.M. Elagolix to medically treat a uterine adenomyoma: A case report. Eur. J. Obstet. Gynecol. Reprod. Biol. 2020 247 266 267 10.1016/j.ejogrb.2020.02.027 32088070
    [Google Scholar]
  77. Donnez O. Donnez J. Gonadotropin-releasing hormone antagonist (linzagolix): A new therapy for uterine adenomyosis. Fertil. Steril. 2020 114 3 640 645 10.1016/j.fertnstert.2020.04.017 32507315
    [Google Scholar]
  78. Syed Y.Y. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids. Drugs 2022 6 1 8
    [Google Scholar]
  79. Donnez J. Liver injury and ulipristal acetate: An overstated tragedy? Fertil. Steril. 2018 110 4 593 595 10.1016/j.fertnstert.2018.06.044 30196943
    [Google Scholar]
  80. Angioni S. D’Alterio M.N. Daniilidis A. Highlights on medical treatment of uterine fibroids. Curr. Pharm. Des. 2021 27 36 3821 3832 10.2174/18734286MTEysOTUkw 33388011
    [Google Scholar]
  81. Ciebiera M. Vitale S.G. Ferrero S. Vilos G.A. Barra F. Caruso S. Laganà A.S. Sierant A. Cianci A. Jakiel G. Vilaprisan, a new selective progesterone receptor modulator in uterine fibroid pharmacotherapy-will it really be a breakthrough? Curr. Pharm. Des. 2020 26 3 300 309 10.2174/1381612826666200127092208 31985366
    [Google Scholar]
  82. Bhatnagar A.S. Brodie A.M.H. Long B.J. Evans D.B. Miller W.R. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J. Steroid Biochem. Mol. Biol. 2001 76 1-5 199 202 10.1016/S0960‑0760(01)00050‑4 11384878
    [Google Scholar]
  83. Moroni R.M. Ferriani R.A. Candido-dos-Reis F.J. Brito L.G.O. Vieira C.S. Pharmacological treatment of uterine fibroids. Ann. Med. Health Sci. Res. 2014 4 9 Suppl. 3 185 10.4103/2141‑9248.141955 25364587
    [Google Scholar]
  84. Vedantham S. Goldhaber S.Z. Julian J.A. Kahn S.R. Jaff M.R. Cohen D.J. Magnuson E. Razavi M.K. Comerota A.J. Gornik H.L. Murphy T.P. Lewis L. Duncan J.R. Nieters P. Derfler M.C. Filion M. Gu C.S. Kee S. Schneider J. Saad N. Blinder M. Moll S. Sacks D. Lin J. Rundback J. Garcia M. Razdan R. VanderWoude E. Marques V. Kearon C. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N. Engl. J. Med. 2017 377 23 2240 2252 10.1056/NEJMoa1615066 29211671
    [Google Scholar]
  85. Barnaby J. Martynov A. Shah S. Ramanathan A. Giant subserosal myoma causing deep venous thrombosis in a patient with pre-existing May-Thurner syndrome. Radiol. Case Rep. 2020 15 6 644 649 10.1016/j.radcr.2020.02.010 32280393
    [Google Scholar]
  86. Chan N. Sobieraj-Teague M. Eikelboom J.W. Direct oral anticoagulants: Evidence and unresolved issues. Lancet 2020 396 10264 1767 1776 10.1016/S0140‑6736(20)32439‑9 33248499
    [Google Scholar]
  87. Schwarb H. Tsakiris D. New direct oral anticoagulants (DOAC) and their use today. Dent. J. 2016 4 1 5 10.3390/dj4010005 29563447
    [Google Scholar]
  88. Müller M. Eastline J. Nagler M. Exadaktylos A.K. Sauter T.C. Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: Indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists. Scand. J. Trauma Resusc. Emerg. Med. 2019 27 1 48 10.1186/s13049‑019‑0625‑3 31014373
    [Google Scholar]
  89. White K. Faruqi U. Cohen A.A.T. New agents for DOAC reversal: A practical management review. Br. J. Cardiol. 2022 29 1 1 35747314
    [Google Scholar]
  90. Binymin K.A. Nasher M. Patel D. Warfarin-induced deep vein thrombosis. Int. Med. Case Rep. J. 2014 7 123 125 10.2147/IMCRJ.S62100 25246809
    [Google Scholar]
  91. Vranckx P. Valgimigli M. Heidbuchel H. The Significance of drug—Drug and drug—Food interactions of oral anticoagulation. Arrhythm. Electrophysiol. Rev. 2018 7 1 55 61 10.15420/aer.2017.50.1 29636974
    [Google Scholar]
  92. Arepally G.M. Heparin-induced thrombocytopenia. Blood 2017 129 21 2864 2872 10.1182/blood‑2016‑11‑709873 28416511
    [Google Scholar]
  93. Ieko M. Tarumi T. Nakabayashi T. Yoshida M. Naito S. Koike T. Factor Xa inhibitors: New anti-thrombotic agents and their characteristics. Front. Biosci. 2006 11 1 232 248 10.2741/1794 16146728
    [Google Scholar]
  94. Arbit B. Nishimura M. Hsu J.C. Reversal agents for direct oral anticoagulants: A focused review. Int. J. Cardiol. 2016 223 244 250 10.1016/j.ijcard.2016.07.304 27541665
    [Google Scholar]
  95. Van Gorp R. Schurgers L. New insights into the pros and cons of the clinical use of vitamin K antagonists (VKAs) versus direct oral anticoagulants (DOACs). Nutrients 2015 7 11 9538 9557 10.3390/nu7115479 26593943
    [Google Scholar]
  96. Goldhaber S.Z. Eriksson H. Kakkar A. Schellong S. Feuring M. Fraessdorf M. Kreuzer J. Schueler E. Schulman S. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER ®, RE-COVER™ II, and RE-MEDY™. Vasc. Med. 2016 21 6 506 514 10.1177/1358863X16668588 27807306
    [Google Scholar]
  97. Diener H.C. Connolly S.J. Ezekowitz M.D. Wallentin L. Reilly P.A. Yang S. Xavier D. Di Pasquale G. Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE-LY trial. Lancet Neurol. 2010 9 12 1157 1163 10.1016/S1474‑4422(10)70274‑X 21059484
    [Google Scholar]
  98. Cohen A.T. Bauersachs R. Rivaroxaban and the EINSTEIN clinical trial programme. Blood Coagul. Fibrinolysis 2019 30 3 85 95 10.1097/MBC.0000000000000800 30920394
    [Google Scholar]
  99. Moik F. Posch F. Zielinski C. Pabinger I. Ay C. Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials. Res. Pract. Thromb. Haemost. 2020 4 4 550 561 10.1002/rth2.12359 32548553
    [Google Scholar]
  100. Stefano V.D. Martinelli I. Rare thromboses of cerebral, splanchnic and upper-extremity veins. Thromb. Haemost. 2010 103 6 1136 1144 10.1160/TH09‑12‑0873 20352171
    [Google Scholar]
  101. Martinelli I. Lensing A.W.A. Middeldorp S. Levi M. Beyer-Westendorf J. van Bellen B. Bounameaux H. Brighton T.A. Cohen A.T. Trajanovic M. Gebel M. Lam P. Wells P.S. Prins M.H. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2016 127 11 1417 1425 10.1182/blood‑2015‑08‑665927 26696010
    [Google Scholar]
  102. Carrier M. Abou-Nassar K. Mallick R. Tagalakis V. Shivakumar S. Schattner A. Kuruvilla P. Hill D. Spadafora S. Marquis K. Trinkaus M. Tomiak A. Lee A.Y.Y. Gross P.L. Lazo-Langner A. El-Maraghi R. Goss G. Le Gal G. Stewart D. Ramsay T. Rodger M. Witham D. Wells P.S. Apixaban to prevent venous thromboembolism in patients with cancer. N. Engl. J. Med. 2019 380 8 711 719 10.1056/NEJMoa1814468 30511879
    [Google Scholar]
  103. Raskob G. Ageno W. Cohen A.T. Brekelmans M.P.A. Grosso M.A. Segers A. Meyer G. Verhamme P. Wells P.S. Lin M. Winters S.M. Weitz J.I. Büller H.R. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 3 5 e228 e236 10.1016/S2352‑3026(16)00023‑5 27132697
    [Google Scholar]
  104. Skjøth F. Larsen T.B. Rasmussen L.H. Lip G.Y. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb. Haemost. 2014 111 5 981 988 24577485
    [Google Scholar]
/content/journals/crcep/10.2174/0127724328317631240925051326
Loading
Bleeding vs Thrombosis: Treatment Strategy for Women Having Large Uterine Fibroids and DVT
Bentham Science Publishers ; https://doi.org/10.2174/0127724328317631240925051326
/content/journals/crcep/10.2174/0127724328317631240925051326
/content/journals/crcep/10.2174/0127724328317631240925051326
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: deep venous thrombosis ; progesterone ; Uterine fibroids ; hypothyroidism ; heavy mensuration bleeding ; anticoagulants

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test